Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPH NYSE:BHC NASDAQ:CTMX NASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$15.82-0.2%$15.75$7.28▼$16.88$2.04B1.411.17 million shs673,625 shsBHCBausch Health Cos$5.06-2.0%$5.46$4.93▼$8.69$1.93B0.41.78 million shs1.85 million shsCTMXCytomX Therapeutics$3.01+1.0%$3.93$1.72▼$8.21$507.16M2.083.32 million shs2.05 million shsPHVSPharvaris$30.72-4.6%$29.57$16.00▼$33.33$2.11B-2.35341,898 shs180,201 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+1.21%-3.18%-0.88%+13.62%+95.92%BHCBausch Health Cos+0.19%-1.72%-4.63%+3.83%-3.19%CTMXCytomX Therapeutics+2.92%-5.82%-22.81%-36.00%+6.21%PHVSPharvaris+2.19%+1.80%+3.04%+26.67%+88.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$15.82-0.2%$15.75$7.28▼$16.88$2.04B1.411.17 million shs673,625 shsBHCBausch Health Cos$5.06-2.0%$5.46$4.93▼$8.69$1.93B0.41.78 million shs1.85 million shsCTMXCytomX Therapeutics$3.01+1.0%$3.93$1.72▼$8.21$507.16M2.083.32 million shs2.05 million shsPHVSPharvaris$30.72-4.6%$29.57$16.00▼$33.33$2.11B-2.35341,898 shs180,201 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+1.21%-3.18%-0.88%+13.62%+95.92%BHCBausch Health Cos+0.19%-1.72%-4.63%+3.83%-3.19%CTMXCytomX Therapeutics+2.92%-5.82%-22.81%-36.00%+6.21%PHVSPharvaris+2.19%+1.80%+3.04%+26.67%+88.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 2.33Hold$17.259.04% UpsideBHCBausch Health Cos 1.80Reduce$8.0058.26% UpsideCTMXCytomX Therapeutics 2.91Moderate Buy$12.10301.99% UpsidePHVSPharvaris 2.69Moderate Buy$49.1860.10% UpsideCurrent Analyst Ratings BreakdownLatest CTMX, AUPH, PHVS, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.005/19/2026CTMXCytomX Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$6.005/15/2026AUPHAurinia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)5/13/2026PHVSPharvaris UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$74.005/13/2026PHVSPharvaris Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$75.00 ➝ $74.005/11/2026CTMXCytomX Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$17.00 ➝ $11.005/4/2026BHCBausch Health Cos Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/1/2026AUPHAurinia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)4/27/2026BHCBausch Health Cos Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$10.00 ➝ $9.004/21/2026PHVSPharvaris Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026PHVSPharvaris CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$283.05M7.19$1.01 per share15.64$4.41 per share3.59BHCBausch Health Cos$10.27B0.18$7.12 per share0.71$1.02 per share4.96CTMXCytomX Therapeutics$76.20M6.72N/AN/A$0.58 per share5.19PHVSPharvarisN/AN/AN/AN/A$4.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals$287.20M$2.1717.6119.78N/A99.97%26.62%19.65%7/30/2026 (Estimated)BHCBausch Health Cos$157M-$3.241.321.34N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)CTMXCytomX Therapeutics-$17.37M-$0.41N/AN/AN/A-166.40%-36.61%-28.02%8/6/2026 (Estimated)PHVSPharvaris-$198.79M-$3.18N/AN/AN/AN/A-67.56%-61.13%8/11/2026 (Estimated)Latest CTMX, AUPH, PHVS, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PHVSPharvaris-$0.8219-$0.70+$0.1219-$0.69N/AN/A5/7/2026Q1 2026AUPHAurinia Pharmaceuticals$0.18$0.25+$0.07$0.25$76.98 million$77.71 million5/7/2026Q1 2026CTMXCytomX Therapeutics-$0.14-$0.10+$0.04-$0.10$4.68 million$10.26 million4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billion4/3/2026Q4 2025PHVSPharvaris-$0.69-$0.84-$0.15-$0.84N/AN/A3/16/2026Q4 2025CTMXCytomX Therapeutics-$0.08-$0.22-$0.14-$0.22$7.33 million$0.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.085.555.01BHCBausch Health Cos54.681.320.97CTMXCytomX TherapeuticsN/A10.3810.38PHVSPharvarisN/A11.2411.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%BHCBausch Health Cos78.65%CTMXCytomX Therapeutics67.77%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%BHCBausch Health Cos20.67%CTMXCytomX Therapeutics6.60%PHVSPharvaris11.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300128.60 million112.91 millionOptionableBHCBausch Health Cos20,300374.02 million296.71 millionOptionableCTMXCytomX Therapeutics170170.19 million158.96 millionOptionablePHVSPharvaris3065.41 million57.66 millionNot OptionableCTMX, AUPH, PHVS, and BHC HeadlinesRecent News About These CompaniesPharvaris Announces Annual General Meeting of ShareholdersJune 11 at 6:50 AM | globenewswire.comPharvaris (NASDAQ:PHVS) Insider Sells $82,422.90 in StockJune 9 at 5:02 AM | insidertrades.comPharvaris (NASDAQ:PHVS) Raised to Hold at Wall Street ZenJune 6, 2026 | americanbankingnews.comPharvaris N.V. (PHVS) Presents at The 2026 Eastern Allergy Conference - SlideshowMay 30, 2026 | seekingalpha.comPharvaris to Present Clinical Data at the EAACI Annual Congress 2026May 29, 2026 | globenewswire.comPharvaris (NASDAQ:PHVS) Insider Sells $55,967.40 in StockMay 27, 2026 | insidertrades.comPharvaris (NASDAQ:PHVS) Director Elisabeth Bjork Sells 10,000 SharesMay 23, 2026 | insidertrades.comPharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 SharesMay 21, 2026 | insidertrades.comInsider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares of StockMay 20, 2026 | marketbeat.comPharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 10,000 SharesMay 20, 2026 | insidertrades.comPharvaris Equity Raise Supports Late Stage HAE Push And Valuation CaseMay 14, 2026 | finance.yahoo.comPharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comPharvaris Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | globenewswire.comPharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional SharesMay 11, 2026 | finance.yahoo.comPharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional SharesMay 11, 2026 | globenewswire.comPharvaris N.V. Prices Underwritten Offering of 3,874,664 Ordinary Shares at $29.68 Per ShareMay 8, 2026 | quiverquant.comQPharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary SharesMay 8, 2026 | globenewswire.comInsider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 3,700 Shares of StockMay 2, 2026 | insidertrades.comFor Pharvaris Investors, the Director's Sale Matters Less Than What's Coming NextApril 30, 2026 | fool.comPharvaris (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan Sells 7,000 SharesApril 25, 2026 | insidertrades.comBerndt Modig Sells 2,292 Shares of Pharvaris (NASDAQ:PHVS) StockApril 21, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTMX, AUPH, PHVS, and BHC Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$15.82 -0.03 (-0.19%) Closing price 04:00 PM EasternExtended Trading$15.95 +0.13 (+0.82%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Bausch Health Cos NYSE:BHC$5.06 -0.11 (-2.03%) Closing price 03:59 PM EasternExtended Trading$5.06 +0.00 (+0.10%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.CytomX Therapeutics NASDAQ:CTMX$3.01 +0.03 (+1.01%) Closing price 04:00 PM EasternExtended Trading$3.03 +0.02 (+0.66%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Pharvaris NASDAQ:PHVS$30.72 -1.48 (-4.60%) Closing price 04:00 PM EasternExtended Trading$30.76 +0.05 (+0.15%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
